leadf
logo-loader
viewInnoCan Pharma

Full interview: InnoCan Pharma signs deal with ADVA Biotechnology to produce Exosomes with CBD

InnoCann Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has signed a Letter of Intent with ADVA Bio-Technology for exosome manufacturing and development.

Bincovich telling Proactive InnoCan intends to load the produced exosomes with CBD and then will be used in the development of therapy for COVID-19 disease and other indications of the central nervous system.

Quick facts: InnoCan Pharma

Price: 0.28 CAD

CSE:INNO
Market: CSE
Market Cap: $49.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Innocan Pharma received U.S. FDA approval for their over the counter CBD...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection. Bincovich talks about the collection and when they would...

on 07/20/2020

2 min read